CN109157742B - 用于刺激肠道内肠促胰岛素产生的吞咽式囊和方法 - Google Patents
用于刺激肠道内肠促胰岛素产生的吞咽式囊和方法 Download PDFInfo
- Publication number
- CN109157742B CN109157742B CN201810714885.XA CN201810714885A CN109157742B CN 109157742 B CN109157742 B CN 109157742B CN 201810714885 A CN201810714885 A CN 201810714885A CN 109157742 B CN109157742 B CN 109157742B
- Authority
- CN
- China
- Prior art keywords
- capsule
- intestinal tract
- cells
- electrodes
- sensor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 197
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 55
- 239000000859 incretin Substances 0.000 title claims abstract description 38
- 230000004936 stimulating effect Effects 0.000 title claims abstract description 17
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title abstract description 23
- 238000004519 manufacturing process Methods 0.000 title abstract description 21
- 230000009747 swallowing Effects 0.000 title description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 64
- 230000000638 stimulation Effects 0.000 claims abstract description 53
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims abstract description 36
- 102000004877 Insulin Human genes 0.000 claims abstract description 32
- 108090001061 Insulin Proteins 0.000 claims abstract description 32
- 229940125396 insulin Drugs 0.000 claims abstract description 32
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims abstract 2
- 230000002572 peristaltic effect Effects 0.000 claims description 40
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims description 35
- 230000008602 contraction Effects 0.000 claims description 35
- 210000000813 small intestine Anatomy 0.000 claims description 22
- 230000000968 intestinal effect Effects 0.000 claims description 18
- 230000003914 insulin secretion Effects 0.000 claims description 7
- 230000033001 locomotion Effects 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 229910001416 lithium ion Inorganic materials 0.000 claims description 2
- 239000003990 capacitor Substances 0.000 claims 1
- 210000003736 gastrointestinal content Anatomy 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 29
- 208000008589 Obesity Diseases 0.000 abstract description 11
- 235000020824 obesity Nutrition 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 9
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 34
- 210000000936 intestine Anatomy 0.000 description 28
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 22
- 239000008103 glucose Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 17
- 235000012054 meals Nutrition 0.000 description 13
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 235000013305 food Nutrition 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000036279 refractory period Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010017982 Gastrointestinal necrosis Diseases 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000001934 delay Effects 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002473 insulinotropic effect Effects 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000003880 negative regulation of appetite Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- 102400000319 Oxyntomodulin Human genes 0.000 description 2
- 101800001388 Oxyntomodulin Proteins 0.000 description 2
- 230000005679 Peltier effect Effects 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- GTKRFUAGOKINCA-UHFFFAOYSA-M chlorosilver;silver Chemical compound [Ag].[Ag]Cl GTKRFUAGOKINCA-UHFFFAOYSA-M 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000009451 Hyperglycemic Hyperosmolar Nonketotic Coma Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000009979 Traumatic Amputation Diseases 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 229940095884 glucophage Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000003979 response to food Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36007—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of urogenital or gastrointestinal organs, e.g. for incontinence control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0507—Electrodes for the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0507—Electrodes for the digestive system
- A61N1/0509—Stomach and intestinal electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/37211—Means for communicating with stimulators
- A61N1/37217—Means for communicating with stimulators characterised by the communication link, e.g. acoustic or tactile
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/06—Electrodes for high-frequency therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Electrotherapy Devices (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27338909P | 2009-08-03 | 2009-08-03 | |
| US61/273,389 | 2009-08-03 | ||
| PCT/US2010/044265 WO2011017335A1 (en) | 2009-08-03 | 2010-08-03 | Swallowable capsule and method for stimulating incretin production within the intestinal tract |
| CN201080034437.7A CN102770151B (zh) | 2009-08-03 | 2010-08-03 | 用于刺激肠道内肠促胰岛素产生的吞咽式囊和方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080034437.7A Division CN102770151B (zh) | 2009-08-03 | 2010-08-03 | 用于刺激肠道内肠促胰岛素产生的吞咽式囊和方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109157742A CN109157742A (zh) | 2019-01-08 |
| CN109157742B true CN109157742B (zh) | 2022-04-05 |
Family
ID=43544631
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810714885.XA Active CN109157742B (zh) | 2009-08-03 | 2010-08-03 | 用于刺激肠道内肠促胰岛素产生的吞咽式囊和方法 |
| CN201080034437.7A Expired - Fee Related CN102770151B (zh) | 2009-08-03 | 2010-08-03 | 用于刺激肠道内肠促胰岛素产生的吞咽式囊和方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080034437.7A Expired - Fee Related CN102770151B (zh) | 2009-08-03 | 2010-08-03 | 用于刺激肠道内肠促胰岛素产生的吞咽式囊和方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (10) | US8682440B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2461818B1 (cg-RX-API-DMAC7.html) |
| JP (8) | JP5854513B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN109157742B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2010279575B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011017335A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8682440B2 (en) | 2009-08-03 | 2014-03-25 | Incube Labs, Llc | Swallowable capsule and method for stimulating incretin production within the intestinal tract |
| US8721620B2 (en) | 2009-12-24 | 2014-05-13 | Rani Therapeutics, Llc | Swallowable drug delivery device and methods of drug delivery |
| CN105168174B (zh) * | 2010-03-10 | 2019-01-08 | 拉尼医疗有限公司 | 用于利用可吞咽式药剂递送装置递送到肠道内腔中的治疗剂制剂 |
| US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9284367B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402807B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8980822B2 (en) | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9861683B2 (en) | 2010-12-23 | 2018-01-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8846040B2 (en) | 2010-12-23 | 2014-09-30 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8809271B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9149617B2 (en) | 2010-12-23 | 2015-10-06 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
| US8969293B2 (en) | 2010-12-23 | 2015-03-03 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
| US10639272B2 (en) | 2010-12-23 | 2020-05-05 | Rani Therapeutics, Llc | Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9283179B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9629799B2 (en) | 2010-12-23 | 2017-04-25 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8764733B2 (en) | 2010-12-23 | 2014-07-01 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| WO2013143603A1 (en) * | 2012-03-30 | 2013-10-03 | Ethicon Endo-Surgery, Inc. | Devices and methods for the treatment of metabolic disorders |
| US20140051924A1 (en) * | 2012-08-16 | 2014-02-20 | Capso Vision, Inc | In Vivo Capsule Device with Electrodes |
| WO2015042558A1 (en) * | 2013-09-23 | 2015-03-26 | Board Of Regents, The University Of Texas System | Wireless tissue stimulation devices |
| US10689460B2 (en) | 2014-05-15 | 2020-06-23 | Incube Labs, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| WO2015176031A2 (en) | 2014-05-15 | 2015-11-19 | Incube Labs, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| US9919152B2 (en) * | 2014-11-05 | 2018-03-20 | Enterastim, Inc. | Conditional gastrointestinal stimulation for improved motility |
| US20160183878A1 (en) * | 2014-12-27 | 2016-06-30 | John C. Weast | Technologies for managing device functions of an ingestible computing device |
| US10500127B2 (en) * | 2016-04-18 | 2019-12-10 | Ankon Medical Technologies (Shanghai) Co., Ltd. | Vivo device and method of using the same |
| WO2018026720A1 (en) * | 2016-07-31 | 2018-02-08 | Hans Gregersen | Autoexpandable devices for obtaining impedance, pressure, and other measurements in the gastrointestinal tract and other organs |
| EP3296727B1 (en) * | 2016-09-19 | 2019-04-17 | Murata Integrated Passive Solutions | Electrical stimulation and monitoring device |
| IL250090B (en) | 2017-01-12 | 2018-10-31 | Melcap Systems Ltd | A capsule is intended for ingestion by a subject and a system is intended for the digestive system |
| US11207272B2 (en) | 2017-05-17 | 2021-12-28 | Massachusetts Institute Of Technology | Tissue anchoring articles |
| US11541015B2 (en) | 2017-05-17 | 2023-01-03 | Massachusetts Institute Of Technology | Self-righting systems, methods, and related components |
| CN108742590A (zh) * | 2018-04-08 | 2018-11-06 | 南京宽诚科技有限公司 | 一种胃肠电信号的采集方法、装置、采集设备及存储介质 |
| US11202903B2 (en) | 2018-05-17 | 2021-12-21 | Massachusetts Institute Of Technology | Systems for electrical stimulation |
| WO2019227150A1 (en) * | 2018-05-31 | 2019-12-05 | Neuroscience Research Australia (Neura) | Systems, devices and methods for the treatment of oral and pharyngeal disorders |
| CN109498989A (zh) * | 2018-12-20 | 2019-03-22 | 宁波贝思转化医学研究中心有限公司 | 一种用于判断胃肠电刺激是否有效的装置及其使用方法 |
| JP2020108458A (ja) * | 2018-12-28 | 2020-07-16 | 株式会社三洋物産 | 遊技機 |
| JP2020108456A (ja) * | 2018-12-28 | 2020-07-16 | 株式会社三洋物産 | 遊技機 |
| JP2020108454A (ja) * | 2018-12-28 | 2020-07-16 | 株式会社三洋物産 | 遊技機 |
| JP2020108457A (ja) * | 2018-12-28 | 2020-07-16 | 株式会社三洋物産 | 遊技機 |
| US11771829B2 (en) | 2019-02-01 | 2023-10-03 | Massachusetts Institute Of Technology | Systems and methods for liquid injection |
| MX2021010450A (es) | 2019-03-01 | 2021-12-10 | Rani Therapeutics Llc | Dispositivos, sistemas y métodos para administrar agentes terapéuticos en la pared de un estómago. |
| US20230317230A1 (en) * | 2019-05-02 | 2023-10-05 | Closed Loop Medicine Ltd. | Method for treating obesity |
| JP7291896B2 (ja) * | 2019-09-24 | 2023-06-16 | パナソニックＩｐマネジメント株式会社 | レシピ出力方法、レシピ出力システム |
| US11541216B2 (en) | 2019-11-21 | 2023-01-03 | Massachusetts Institute Of Technology | Methods for manufacturing tissue interfacing components |
| KR102608853B1 (ko) * | 2021-11-15 | 2023-12-01 | 재단법인 아산사회복지재단 | 대사질환 개선용 생체발광 캡슐 |
| US20240415429A1 (en) * | 2023-06-14 | 2024-12-19 | University Of Maryland, College Park | Real-time ingestible sensing capsule |
Family Cites Families (179)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3788322A (en) | 1972-12-27 | 1974-01-29 | Alza Corp | Drug delivery device with means for maintaining device in environment of use |
| US4249531A (en) | 1979-07-05 | 1981-02-10 | Alza Corporation | Bioerodible system for delivering drug manufactured from poly(carboxylic acid) |
| DE2928477C3 (de) | 1979-07-14 | 1982-04-15 | Battelle-Institut E.V., 6000 Frankfurt | Vorrichtung zur Freisetzung von Substanzen an definierten Orten des Verdauungstraktes |
| JPS60129057A (ja) | 1983-12-14 | 1985-07-10 | 住友化学工業株式会社 | 針状固形製剤投与針 |
| US4596819A (en) | 1984-01-23 | 1986-06-24 | Warner-Lambert Company | Modified tripeptides |
| US4663308A (en) | 1984-07-18 | 1987-05-05 | Medical College Of Ohio | Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointestinal tract |
| FR2597351B1 (fr) | 1986-04-16 | 1994-03-25 | Celsa Composants Electriques | Capsule distributrice de drogue implantable et procede et dispositif facilitant son utilisation. |
| US5137669A (en) | 1988-03-02 | 1992-08-11 | Endocon, Inc. | Manufacture of partially fused peptide pellet |
| JP2691937B2 (ja) | 1988-07-05 | 1997-12-17 | カンテニース，ジョゼ | 胃内バルーン |
| US5271945A (en) | 1988-07-05 | 1993-12-21 | Takeda Chemical Industries, Ltd. | Sustained release microcapsule for water soluble drug |
| US5474785A (en) | 1990-01-24 | 1995-12-12 | Alza Corporation | Delivery system comprising means for controlling internal pressure |
| US5217449A (en) | 1990-12-11 | 1993-06-08 | Miyarisan Kabushiki Kaisha | Medical capsule and apparatus for activating the same |
| US5279607A (en) | 1991-05-30 | 1994-01-18 | The State University Of New York | Telemetry capsule and process |
| PT100944B (pt) | 1991-10-10 | 2000-02-29 | Alza Corp | Dispositivo para o fornecimento osmotico de farmacos com paredes de materiais hidrofobicos |
| US5318557A (en) | 1992-07-13 | 1994-06-07 | Elan Medical Technologies Limited | Medication administering device |
| DK42093D0 (da) | 1993-04-07 | 1993-04-07 | Bukh Meditec | Administrationsmetode |
| US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
| US5652216A (en) | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
| US5849327A (en) | 1994-07-29 | 1998-12-15 | Advanced Polymer Systems, Inc. | Delivery of drugs to the lower gastrointestinal tract |
| US5904935A (en) | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
| US5750926A (en) | 1995-08-16 | 1998-05-12 | Alfred E. Mann Foundation For Scientific Research | Hermetically sealed electrical feedthrough for use with implantable electronic devices |
| US5620476A (en) | 1995-11-13 | 1997-04-15 | Pacesetter, Inc. | Implantable medical device having shielded and filtered feedthrough assembly and methods for making such assembly |
| US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5987358A (en) | 1998-02-17 | 1999-11-16 | Intermedics, Inc. | Semiconductor device packaging and method of fabrication |
| IT1299266B1 (it) | 1998-05-15 | 2000-02-29 | Sigma Tau Ind Farmaceuti | Inibitori reversibili della carnitina palmitoil trasferasi |
| US6395273B1 (en) | 1998-06-10 | 2002-05-28 | Promega Corporation | Prevention and treatment of inflammatory bowel disease |
| US8700161B2 (en) * | 1999-03-05 | 2014-04-15 | Metacure Limited | Blood glucose level control |
| AU2937600A (en) * | 1999-03-05 | 2000-09-28 | Impulse Dynamics N.V. | Blood glucose level control |
| WO2004112563A2 (en) * | 2003-06-20 | 2004-12-29 | Metacure N.V., | Gastrointestinal methods and apparatus for use in treating disorders |
| US6743211B1 (en) | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
| GB9930000D0 (en) | 1999-12-21 | 2000-02-09 | Phaeton Research Ltd | An ingestible device |
| GB0017999D0 (en) | 2000-07-21 | 2000-09-13 | Smithkline Beecham Biolog | Novel device |
| US6832114B1 (en) * | 2000-11-21 | 2004-12-14 | Advanced Bionics Corporation | Systems and methods for modulation of pancreatic endocrine secretion and treatment of diabetes |
| US6638246B1 (en) | 2000-11-28 | 2003-10-28 | Scimed Life Systems, Inc. | Medical device for delivery of a biologically active material to a lumen |
| EP1345968A2 (en) | 2000-12-28 | 2003-09-24 | Altus Biologics Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| US7069081B2 (en) | 2001-02-08 | 2006-06-27 | Wilson Greatbatch Ltd. | One piece header assembly for an implantable medical device |
| EP1386155A4 (en) | 2001-04-10 | 2006-05-10 | Univ Leland Stanford Junior | THERAPEUTIC AND DIAGNOSTIC USE OF ANTIBODY SPECIFICITY PROFILES |
| US7787958B2 (en) | 2001-04-13 | 2010-08-31 | Greatbatch Ltd. | RFID detection and identification system for implantable medical lead systems |
| US7160258B2 (en) | 2001-06-26 | 2007-01-09 | Entrack, Inc. | Capsule and method for treating or diagnosing the intestinal tract |
| US7083578B2 (en) | 2001-07-12 | 2006-08-01 | Given Imaging Ltd. | Device and method for examining a body lumen |
| US20070162085A1 (en) * | 2001-07-23 | 2007-07-12 | Dilorenzo Biomedical, Llc | Method, apparatus, surgical technique, and stimulation parameters for autonomic neuromodulation for the treatment of obesity |
| US20030226155A1 (en) | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| JP4643089B2 (ja) | 2001-09-27 | 2011-03-02 | オリンパス株式会社 | カプセル型医療装置 |
| JP2002186672A (ja) | 2001-09-28 | 2002-07-02 | Olympus Optical Co Ltd | 医療用カプセル装置 |
| WO2003028653A2 (en) | 2001-10-03 | 2003-04-10 | Glaxo Group Limited | Sustained release pharmaceutical compositions |
| US6656155B2 (en) | 2001-12-17 | 2003-12-02 | Scimed Life Systems, Inc. | Catheter for endoluminal delivery of therapeutic agents that minimizes loss of therapeutic |
| FR2835730B1 (fr) | 2002-02-11 | 2004-12-10 | C T M Ct De Transfert Des Micr | Dispositif pour la delivrance de substances et le prelevement intracorporel |
| US20030186892A1 (en) | 2002-03-28 | 2003-10-02 | Rajneesh Taneja | Enhancement of endogenous gonadotropin production |
| AU2003275311A1 (en) | 2002-09-16 | 2004-04-30 | Sung-Yun Kwon | Solid micro-perforators and methods of use |
| US7118531B2 (en) | 2002-09-24 | 2006-10-10 | The Johns Hopkins University | Ingestible medical payload carrying capsule with wireless communication |
| AU2002951739A0 (en) | 2002-09-30 | 2002-10-17 | Cochlear Limited | Feedthrough with multiple conductive pathways extending therethrough |
| US20040106904A1 (en) | 2002-10-07 | 2004-06-03 | Gonnelli Robert R. | Microneedle array patch |
| US20040093039A1 (en) * | 2002-10-25 | 2004-05-13 | Raphael Schumert | Gastrointestinal pacemaker |
| ATE547976T1 (de) | 2002-12-26 | 2012-03-15 | Given Imaging Ltd | Immobilisierbare in-vivo messvorrichtung |
| US20040143221A1 (en) | 2002-12-27 | 2004-07-22 | Shadduck John H. | Biomedical implant for sustained agent release |
| CA2514392A1 (en) | 2003-01-29 | 2004-08-12 | E-Pill Pharma Ltd. | Active drug delivery in the gastrointestinal tract |
| US20050058701A1 (en) | 2003-01-29 | 2005-03-17 | Yossi Gross | Active drug delivery in the gastrointestinal tract |
| US20040267240A1 (en) | 2003-01-29 | 2004-12-30 | Yossi Gross | Active drug delivery in the gastrointestinal tract |
| JP2005021677A (ja) | 2003-06-10 | 2005-01-27 | Medorekkusu:Kk | 経皮投薬用パッドベース、及び注射針 |
| JP2007525472A (ja) | 2003-07-04 | 2007-09-06 | ニコメド ダンマーク エイピーエス | 経口使用のための副甲状腺ホルモン（ｐｔｈ）含有医薬組成物 |
| US20070060971A1 (en) * | 2003-07-21 | 2007-03-15 | Ofer Glasberg | Hepatic device for treatment or glucose detection |
| SG145712A1 (en) | 2003-08-01 | 2008-09-29 | Amgen Inc | Crystalline tumor necrosis factor receptor 2 polypeptides |
| US20050038415A1 (en) | 2003-08-06 | 2005-02-17 | Rohr William L. | Method and apparatus for the treatment of obesity |
| US8353861B2 (en) | 2003-09-18 | 2013-01-15 | Texmac, Inc. | Applicator for applying functional substances into human skin |
| AU2004277419B2 (en) | 2003-09-30 | 2007-10-11 | Brown University Research Foundation | Nanoparticulate therapeutic biologically active agents |
| US20050124875A1 (en) | 2003-10-01 | 2005-06-09 | Olympus Corporation | Vivo observation device |
| JP4733918B2 (ja) | 2003-10-01 | 2011-07-27 | オリンパス株式会社 | カプセル投薬システム |
| JP2007526022A (ja) | 2003-10-24 | 2007-09-13 | メドトロニック・インコーポレーテッド | 炎症誘発性媒介物質の産生を減弱することによって神経性障害を処置する技法 |
| US7918786B2 (en) * | 2003-11-11 | 2011-04-05 | Olympus Corporation | Capsule type medical device system, and capsule type medical device |
| JP2005143560A (ja) * | 2003-11-11 | 2005-06-09 | Olympus Corp | カプセル型医療装置 |
| JP4094543B2 (ja) * | 2003-12-26 | 2008-06-04 | オリンパス株式会社 | カプセル型医療装置システム |
| US20050158356A1 (en) | 2003-11-20 | 2005-07-21 | Angiotech International Ag | Implantable sensors and implantable pumps and anti-scarring agents |
| US8585771B2 (en) | 2004-02-26 | 2013-11-19 | Endosphere, Inc. | Methods and devices to curb appetite and/or to reduce food intake |
| MY162179A (en) | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
| US7857767B2 (en) | 2004-04-19 | 2010-12-28 | Invention Science Fund I, Llc | Lumen-traveling device |
| DE102004026615A1 (de) | 2004-06-01 | 2005-12-29 | Siemens Ag | Vorrichtung und Verfahren zur Freisetzung eines in das Körperinnere eines Patienten geführten therapeutischen Mittels |
| JP2006000307A (ja) | 2004-06-16 | 2006-01-05 | Pentax Corp | 酸素発生装置を有するカプセル型医療用具 |
| US20060153894A1 (en) | 2004-06-30 | 2006-07-13 | Ragae Ghabrial | Multi-compartment delivery system |
| CN105708787A (zh) | 2004-07-12 | 2016-06-29 | 爱密斯菲尔科技公司 | 用于递送肽yy和pyy激动剂的组合物 |
| EP1796529B1 (en) | 2004-09-08 | 2016-02-03 | Olympus Corporation | Capsule type medical device |
| US20060063719A1 (en) | 2004-09-21 | 2006-03-23 | Point Therapeutics, Inc. | Methods for treating diabetes |
| WO2006035446A2 (en) | 2004-09-30 | 2006-04-06 | Duocure, Inc. | Device and method for treating weight disorders |
| EP1827387A2 (en) | 2004-12-14 | 2007-09-05 | E-Pill Pharma Ltd. | Prolonged transit time of permeability-enhancing drug eluting pill |
| WO2006074051A2 (en) | 2004-12-30 | 2006-07-13 | Diakine Therapeutics, Inc. | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION |
| US7556826B2 (en) | 2005-01-04 | 2009-07-07 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| CN101107038A (zh) | 2005-01-18 | 2008-01-16 | 皇家飞利浦电子股份有限公司 | 电控胶囊 |
| US7785291B2 (en) | 2005-03-01 | 2010-08-31 | Tulip Medical Ltd. | Bioerodible self-deployable intragastric implants |
| CN2860501Y (zh) | 2005-03-10 | 2007-01-24 | 李华 | 一次性注射器 |
| EP1885437A2 (en) * | 2005-05-19 | 2008-02-13 | E-Pill Pharma Ltd. | Ingestible device for nitric oxide production in tissue |
| CN101184523B (zh) | 2005-05-27 | 2011-04-13 | 奥林巴斯株式会社 | 被检体内导入装置 |
| US20070016262A1 (en) * | 2005-07-13 | 2007-01-18 | Betastim, Ltd. | Gi and pancreatic device for treating obesity and diabetes |
| EP1906830B1 (en) | 2005-07-26 | 2013-09-04 | Ram Weiss | Extending intrabody capsule |
| US8021384B2 (en) | 2005-07-26 | 2011-09-20 | Ram Weiss | Extending intrabody capsule |
| US9198871B2 (en) | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
| PL2347762T3 (pl) | 2005-08-19 | 2019-09-30 | Amylin Pharmaceuticals, Llc | Eksendyna do leczenia cukrzycy i zmniejszania masy ciała |
| AU2006292293B2 (en) | 2005-09-19 | 2012-09-13 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
| US7957796B2 (en) * | 2005-10-28 | 2011-06-07 | Cyberonics, Inc. | Using physiological sensor data with an implantable medical device |
| JP4402648B2 (ja) | 2005-12-16 | 2010-01-20 | オリンパス株式会社 | 被検体内導入装置 |
| GB0603252D0 (en) | 2006-02-17 | 2006-03-29 | Axcess Ltd | Dissolution aids for oral peptide delivery |
| HUE047230T2 (hu) | 2006-02-28 | 2020-04-28 | Biogen Ma Inc | Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei |
| US20060229529A1 (en) | 2006-03-30 | 2006-10-12 | Wright Robert C | System, apparatus, and method for marking orientation of a tissue sample |
| US7818876B2 (en) | 2006-04-25 | 2010-10-26 | Gregg Jorgen Suaning | Method for fabrication of hermetic electrical conductor feedthroughs |
| WO2007136735A2 (en) | 2006-05-18 | 2007-11-29 | Tulip Medical Ltd. | Bioerodible self-deployable intragastric and non-gastric implants |
| US20070288033A1 (en) | 2006-06-09 | 2007-12-13 | Allergan, Inc. | Intragastric balloon retrieval mechanisms |
| EP2684895A1 (en) | 2006-10-27 | 2014-01-15 | AbbVie Biotechnology Ltd | Crystalline anti-hTNFalpha antibodies |
| EP2101643B1 (en) | 2006-10-31 | 2013-04-24 | Medimetrics Personalized Drug Delivery B.V. | Design of swallowable multi-nozzle, dosing device for releasing medicines in the gastrointestinal tract |
| US20080214919A1 (en) | 2006-12-26 | 2008-09-04 | Lifescan, Inc. | System and method for implementation of glycemic control protocols |
| WO2008100974A2 (en) | 2007-02-13 | 2008-08-21 | Sharma Virender K | Method and apparatus for electrical stimulation of the pancreatico-biliary system |
| US8160708B2 (en) | 2007-04-11 | 2012-04-17 | Pacesetter, Inc. | Capacitor-integrated feedthrough assembly with improved grounding for an implantable medical device |
| US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| EP2157967B1 (en) | 2007-04-23 | 2013-01-16 | Intarcia Therapeutics, Inc | Suspension formulations of insulinotropic peptides and uses thereof |
| US9364666B2 (en) | 2007-05-07 | 2016-06-14 | Transtimulation Research, Inc. | Method of using a gastrointestinal stimulator device for digestive and eating disorders |
| US7925351B2 (en) * | 2007-06-13 | 2011-04-12 | Betastim, Ltd. | Gastrointestinal device for treating obesity and diabetes |
| US20090030743A1 (en) | 2007-07-24 | 2009-01-29 | Las Vegas Central Reservation Corp. | Intelligent Hotel Reservation System and Method |
| US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| US7930033B2 (en) | 2007-08-17 | 2011-04-19 | Jianfeng Chen | Appendicular and rectal stimulator device for digestive and eating disorders |
| CN101808567B (zh) | 2007-09-26 | 2012-09-05 | 奥林巴斯医疗株式会社 | 被检体内导入系统 |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| US8215013B2 (en) | 2008-04-11 | 2012-07-10 | Bal Seal Engineering, Inc. | Method for making a free standing axially compressed connector stack |
| WO2009129465A2 (en) | 2008-04-17 | 2009-10-22 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of xbp-1 gene |
| CA2723434C (en) | 2008-05-05 | 2018-01-23 | Oramed Ltd. | Methods and compositions for oral administration of exenatide |
| ATE505128T1 (de) | 2008-06-04 | 2011-04-15 | Olympus Medical Systems Corp | Kapselförmige medizinische vorrichtung |
| US20090317372A1 (en) | 2008-06-20 | 2009-12-24 | Zoltan Kiss | Small molecules for the reduction of high blood glucose level |
| US8287902B2 (en) | 2008-07-23 | 2012-10-16 | Rainbow Medical Ltd. | Enhanced-diffusion capsule |
| BRPI0917925A2 (pt) | 2008-08-26 | 2015-11-10 | Centocor Ortho Biotech Inc | estimulação da liberação de hormônio da saciedade |
| US8948870B2 (en) | 2008-09-09 | 2015-02-03 | Incube Labs, Llc | Energy harvesting mechanism |
| EP2344459B1 (en) | 2008-09-25 | 2013-12-25 | F. Hoffmann-La Roche AG | 2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as fxr modulators against dyslipidemia and related diseases |
| US8535260B2 (en) | 2008-10-15 | 2013-09-17 | Dtherapeutics, Llc | Devices, systems, and methods for localized drug delivery |
| US9072583B2 (en) | 2008-10-16 | 2015-07-07 | Obalon Therapeutics, Inc. | Intragastric volume-occupying device and method for fabricating same |
| WO2010045656A2 (en) | 2008-10-17 | 2010-04-22 | Nectid, Inc. | Novel sglt2 inhibitor dosage forms |
| EP2351511B1 (en) | 2008-11-13 | 2014-04-02 | Olympus Medical Systems Corp. | Capsule medical apparatus |
| US20100131043A1 (en) | 2008-11-26 | 2010-05-27 | Casas Jesus W | Endoluminal Implants For Bioactive Material Delivery |
| WO2010093834A2 (en) | 2009-02-12 | 2010-08-19 | Incube Labs, Llc | Skin penetrating device and method for subcutaneous solid drug delivery |
| EP2440210A4 (en) | 2009-06-12 | 2014-01-29 | Meritage Pharma Inc | METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES |
| US8682440B2 (en) | 2009-08-03 | 2014-03-25 | Incube Labs, Llc | Swallowable capsule and method for stimulating incretin production within the intestinal tract |
| US8834423B2 (en) | 2009-10-23 | 2014-09-16 | University of Pittsburgh—of the Commonwealth System of Higher Education | Dissolvable microneedle arrays for transdermal delivery to human skin |
| US8721620B2 (en) | 2009-12-24 | 2014-05-13 | Rani Therapeutics, Llc | Swallowable drug delivery device and methods of drug delivery |
| CN102905753B (zh) | 2009-12-24 | 2016-06-29 | 因卡伯实验室有限责任公司 | 可吞咽式药剂递送装置和药剂递送方法 |
| CN105168174B (zh) | 2010-03-10 | 2019-01-08 | 拉尼医疗有限公司 | 用于利用可吞咽式药剂递送装置递送到肠道内腔中的治疗剂制剂 |
| US20110295178A1 (en) | 2010-05-26 | 2011-12-01 | Albrecht Thomas E | Intestinal Brake Inducing Intraluminal Therapeutic Substance Eluting Devices and Methods |
| US8876761B2 (en) | 2010-05-26 | 2014-11-04 | Ethicon Endo-Surgery, Inc. | Intestinal brake inducing intraluminal therapeutic substance eluting devices and methods |
| US8603023B2 (en) | 2010-05-26 | 2013-12-10 | Ethicon Endo-Surgery, Inc. | Intestinal brake inducing intraluminal therapeutic substance eluting devices and methods |
| US20110295337A1 (en) | 2010-05-26 | 2011-12-01 | Albrecht Thomas E | Systems and Methods For Regulating Metabolic Hormone Producing Tissue |
| WO2012035559A2 (en) | 2010-09-17 | 2012-03-22 | Panacea Biotec Ltd | Sustained release pharmaceutical compositions comprising pregabalin |
| US9861683B2 (en) | 2010-12-23 | 2018-01-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402807B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9149617B2 (en) | 2010-12-23 | 2015-10-06 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
| US8809271B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8980822B2 (en) | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8764733B2 (en) | 2010-12-23 | 2014-07-01 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8969293B2 (en) | 2010-12-23 | 2015-03-03 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9284367B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9283179B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
| US8846040B2 (en) | 2010-12-23 | 2014-09-30 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9629799B2 (en) | 2010-12-23 | 2017-04-25 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| CN103987422B (zh) | 2011-06-29 | 2017-02-15 | 拉尼医疗有限公司 | 用于治疗化合物的口服递送的装置、系统和方法 |
| ES2773115T3 (es) | 2011-06-29 | 2020-07-09 | Rani Therapeutics Llc | Preparados de agentes terapéuticos para la administración hacia el interior de una luz del tubo intestinal utilizando un dispositivo tragable para la administración de fármacos |
| WO2013143599A1 (en) | 2012-03-30 | 2013-10-03 | Ethicon Endo-Surgery, Inc. | Devices and methods for the treatment of metabolic disorders. |
| WO2013143609A1 (en) | 2012-03-30 | 2013-10-03 | Ethicon Endo-Surgery, Inc. | Devices and methods for the treatment of metabolic disorders |
| US9750660B2 (en) | 2012-03-30 | 2017-09-05 | Ethicon Endo-Surgery, Inc. | Devices and methods for the treatment of metabolic disorders |
| WO2013143603A1 (en) | 2012-03-30 | 2013-10-03 | Ethicon Endo-Surgery, Inc. | Devices and methods for the treatment of metabolic disorders |
| WO2013143600A1 (en) | 2012-03-30 | 2013-10-03 | Ethicon Endo-Surgery, Inc. | Devices and methods for the treatment of metabolic disorders. |
| WO2013165964A1 (en) | 2012-04-30 | 2013-11-07 | Carnegie Mellon University | An ingestible, electrical device for stimulating tissues in a gastrointestinal tract of an organism |
| US8755888B2 (en) | 2012-10-17 | 2014-06-17 | Melcap Systems Ltd. | Gastrointestinal system |
| US9168000B2 (en) | 2013-03-13 | 2015-10-27 | Ethicon Endo-Surgery, Inc. | Meal detection devices and methods |
| EP3964190A1 (en) | 2013-03-15 | 2022-03-09 | Rani Therapeutics, LLC | Device for oral delivery of therapeutic compounds |
| WO2017002104A1 (en) | 2015-06-28 | 2017-01-05 | Yaron Ilan | Devices for gastrointestinal stimulation and uses thereof |
| WO2017004623A1 (en) | 2015-07-02 | 2017-01-05 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| CN105997466B (zh) | 2016-06-16 | 2018-01-26 | 中南民族大学 | 智能型振动电子胶囊 |
| WO2018026720A1 (en) | 2016-07-31 | 2018-02-08 | Hans Gregersen | Autoexpandable devices for obtaining impedance, pressure, and other measurements in the gastrointestinal tract and other organs |
| IL250090B (en) | 2017-01-12 | 2018-10-31 | Melcap Systems Ltd | A capsule is intended for ingestion by a subject and a system is intended for the digestive system |
| WO2018146675A1 (en) | 2017-02-07 | 2018-08-16 | Yaron Ilan | Closed loop organ stimulation |
| US11202903B2 (en) | 2018-05-17 | 2021-12-21 | Massachusetts Institute Of Technology | Systems for electrical stimulation |
| US20230284929A1 (en) | 2022-03-14 | 2023-09-14 | Massachusetts Institute Of Technology | Vibrating Ingestible Capsule |
-
2010
- 2010-08-03 US US12/849,574 patent/US8682440B2/en active Active
- 2010-08-03 EP EP10807036.8A patent/EP2461818B1/en active Active
- 2010-08-03 AU AU2010279575A patent/AU2010279575B2/en not_active Ceased
- 2010-08-03 JP JP2012523704A patent/JP5854513B2/ja active Active
- 2010-08-03 EP EP18191332.8A patent/EP3466438A1/en not_active Withdrawn
- 2010-08-03 WO PCT/US2010/044265 patent/WO2011017335A1/en not_active Ceased
- 2010-08-03 CN CN201810714885.XA patent/CN109157742B/zh active Active
- 2010-08-03 CN CN201080034437.7A patent/CN102770151B/zh not_active Expired - Fee Related
-
2014
- 2014-02-12 US US14/179,215 patent/US8781591B2/en active Active
- 2014-05-09 US US14/273,917 patent/US8958879B2/en active Active
- 2014-10-22 JP JP2014215009A patent/JP2015042285A/ja not_active Withdrawn
-
2015
- 2015-01-16 US US14/599,350 patent/US9403002B2/en active Active
-
2016
- 2016-05-12 AU AU2016203077A patent/AU2016203077B2/en not_active Ceased
- 2016-06-24 US US15/192,928 patent/US9643005B2/en active Active
-
2017
- 2017-01-06 JP JP2017000868A patent/JP2017121487A/ja not_active Withdrawn
- 2017-04-11 US US15/485,031 patent/US9987487B2/en active Active
-
2019
- 2019-08-27 US US16/552,570 patent/US11439817B2/en active Active
- 2019-11-07 JP JP2019202441A patent/JP2020032236A/ja active Pending
-
2022
- 2022-02-01 JP JP2022014190A patent/JP7143539B2/ja active Active
- 2022-08-10 US US17/885,049 patent/US11872396B2/en active Active
- 2022-08-16 JP JP2022129621A patent/JP7341297B2/ja active Active
-
2023
- 2023-08-10 JP JP2023130936A patent/JP7788058B2/ja active Active
- 2023-12-07 US US18/532,183 patent/US12403308B2/en active Active
-
2025
- 2025-01-24 JP JP2025010861A patent/JP2025061805A/ja active Pending
- 2025-07-31 US US19/287,484 patent/US20260199673A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7788058B2 (ja) | 腸管内でインクレチン生産を刺激するための嚥下可能カプセルおよび方法 | |
| US8934975B2 (en) | Gastrointestinal electrical therapy | |
| EP1868679B1 (en) | Non-immediate effects of therapy | |
| JP2013501060A5 (cg-RX-API-DMAC7.html) | ||
| EP1735047A2 (en) | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar | |
| WO2006087717A2 (en) | Non-immediate effects of therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |